Explore the concept of disease modification in atopic dermatitis through this interactive infographic, which highlights potential considerations such as optimal sustained disease control, subclinical inflammation, the pathophysiology of AD, and atopic/non-atopic comorbidities.

Learn how the multidimensional, cumulative burdens of atopic dermatitis extend beyond the skin and across multiple organ systems, manifesting as atopic and non-atopic comorbidities. Even when an individual is performing well in spite of these burdens, they may still have significant life course impairment due to the cumulative impact of the disease.
The ADVENT symposium at the 15th World Congress of Pediatric Dermatology (WCPD) will focus on discussions around disease modification in atopic dermatitis (AD) in three main topic areas: restoring the skin barrier, reducing non-atopic comorbidities, and stopping the atopic march in pediatric patients with AD aged 6 months to 11 years.

Dr. Jason Hawkes provides key pathophysiologic insights and debunks common misconceptions surrounding atopic dermatitis.
Dr. Ahuva Cices provides key pathophysiologic insights and dispels common misconceptions surrounding atopic dermatitis.

In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.
Dr. David Cotter discusses how atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis present uniquely in practice—and how type 2 inflammation links these distinct disease states.

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression

Dr. Jason Hawkes explores the unique clinical manifestations of atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis, while highlighting the shared role of type 2 inflammation across these distinct diseases.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson explains how both clinical and subclinical disease control are critical for achieving true disease modification in atopic dermatitis, emphasizing the role of biomarkers in predicting long-term outcomes and guiding treatment decisions.
In this webinar, Drs. David Cotter, Daniel Butler, and Walter Liszewski share key clinical insights, highlighting the central role of type 2 inflammation across atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria while addressing prevalent scientific misconceptions.
This symposium highlights the central role of type 2 inflammation in atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria and dismantles prevalent scientific misconceptions about these inflammatory skin conditions with lively discussion from Drs Jason Hawkes, Lakshi Aldredge and Diego Dasilva.